scholarly journals Side effects of 1% cyclopentolate hydrochloride in children and adolescents attended at Centro Universitário FMABC

2020 ◽  
Vol 45 (Suppl.3) ◽  
pp. e020106
Author(s):  
Ianna Luiza Avelino Valentino ◽  
Celso Lopez Fernandez ◽  
Fernando Luiz Affonso Fonseca ◽  
Glaucia Luciano da Veiga ◽  
Vagner Loduca Lima
Keyword(s):  
Side Effects ◽  
Signs And Symptoms ◽  
Point Of View ◽  
Eye Drops ◽  
Ophthalmological Examination ◽  
Vision Disorders ◽  
Ocular Side ◽  
Spontaneous Reversal ◽  
Systemic Side Effects ◽  
Systemic Symptoms

Introduction: It is known that vision disorders are within the context of public health problems. In childhood, during the neuropsychomotor development phase, visual changes are crucial, since there is a strong correlation between poor school performance and changes in acuity. For these reasons, ophthalmological examination in children, including refraction, is extremely important, aiming at the early diagnosis of diseases and possible refractive errors that may compromise the child's life and development. 1% cyclopentolate hydrochloride eye drops are the most used during ophthalmic clinical evaluation as a cycloplegic and mydriatic agent to assist in refractive examination. Objective: The ocular and systemic side effects of 1% cyclopentolate hydrochloride eye drops were studied in patients who underwent static refractive examination in the strabismus sector of the Ophthalmology Discipline of the Centro Universitário FMABC. Methods: A drop of 1% cyclopentolate is instilled in both eyes of each patient and the possible ocular and systemic signs and symptoms presented were observed after 40 minutes and 24 hours after instillation. Results: we expect to find ocular side effects more evident than systemic symptoms in the two evaluation times (40 minutes and 24 hours after instillation). All symptoms (ocular and systemic) are reversed spontaneously. Conclusion: The present study aims to show that the side effects observed by the topical (ocular) use of cyclopentolate eye drops 1% are few and present spontaneous reversal both from an eye point of view, as well as from a systemic point of view.

scholarly journals What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects

2020 ◽  
pp. 112067212095832
Author(s):  
Isabel Fambuena-Muedra ◽  
Marta Jiménez-García ◽  
Sarah Hershko ◽  
Irene Altemir-Gómez ◽  
Ana Tobarra-López
Keyword(s):  
Clinical Trials ◽  
Side Effects ◽  
Exclusion Criterion ◽  
Ophthalmological Examination ◽  
Ocular Side ◽  
Short Period ◽  
Repurposed Drugs ◽  
Detailed Search ◽  
Ocular Side Effect

Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Collection. Additionally, the worldwide ongoing clinical trials including chloroquine or hydroxychloroquine were evaluated, and their proposals of drug administration and exclusion criteria analyzed. In general, high maximum cumulative doses of chloroquine or hydroxychloroquine are being used for a short period in 135 currently underway clinical trials (to 21st April 2020). Typically, the doses were 2 to 5 times greater than the AAO recommendation (adjusted to weight) to avoid toxic retinopathy, the most undesirable ocular side effect. Maximum cumulative doses up to 12,000 mg for chloroquine and 18,000 mg for hydroxychloroquine were found. In prophylaxis clinical trials, 72,000 mg and 22,500 mg were the maximum cumulative doses for hydroxychloroquine and chloroquine respectively. Only 48% of the clinical trials considered retinal impairment as an exclusion criterion, and just one referred to an ophthalmic examination previous to study inclusion. How chloroquine and hydroxychloroquine treatment affect patients with a previous retinal condition is still poorly understood. A comprehensive ophthalmological examination 6 months after treatment is recommended in this subgroup. This review provides an overview of this topic and sheds light on the challenges visual caregivers may face regarding these repurposed drugs.

scholarly journals Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan®) in children

Eye ◽  
2004 ◽  
Vol 18 (1) ◽  
pp. 24-26 ◽  
Author(s):  
R J C Bowman ◽  
J Cope ◽  
K K Nischal
Keyword(s):  
Side Effects ◽  
Eye Drops ◽  
Systemic Side Effects

scholarly journals AYURVEDIC MANAGEMENT OF BRONCHIAL ASTHMA – A CASE STUDY

2020 ◽  
Vol 8 (10) ◽  
pp. 4894-4901
Author(s):  
Momin Jasmin Begam ◽  
Kulkarni Prasad ◽  
Gogate Vishwas
Keyword(s):  
Side Effects ◽  
Environmental Factors ◽  
Bronchial Asthma ◽  
Clinical Picture ◽  
Signs And Symptoms ◽  
Breathing Difficulty ◽  
Systemic Side Effects ◽  
Genetic And Environmental Factors ◽  
Present Case Study

Bronchial asthma is a heterogenous disease with reciprocity between genetic and environmental factors. The different triggering factors increase the frequency and severity of breathing difficulty attacks. The use of modern medicines is restricted due to its various local as well systemic side effects. The clinical picture of bronchial asthma can be correlated with Tamakashwas as explained in Ayurveda. In the present case study, a 24 years old female patient having signs and symptoms of Tamakashwas has been discussed. The treatment was administered in accordance with Shodhana Chikitsa, Shamana Aushadhis and Sthanika Chikitsa. Nidana Parivarjana is strictly instructed in order to avoid the stimulation to internal pathology of the disease. The classical management helps in relieving the symptoms as well as lowers the recurrence of the breathing difficulty attacks. Regular counselling and practice of Parnayama contributes in boosting and refreshing her mind. The assessment was done by using the gradation scale which was adopted from de-veloping guidelines for clinical research methodology in Ayurveda. This Ayurvedic management helps in achieving the positive output with complete stoppage of use of inhaler over a period of 6 months.

scholarly journals Systemic side effects of eye drops: a pharmacokinetic perspective

2016 ◽  
Vol Volume 10 ◽  
pp. 2433-2441 ◽  
Author(s):  
Andre Farkouh ◽  
Peter Frigo ◽  
Martin Czejka
Keyword(s):  
Side Effects ◽  
Eye Drops ◽  
Systemic Side Effects

scholarly journals Severe Corticosteroid-Induced Ocular Hypertension Requiring Bilateral Trabeculectomies in a Patient with Takayasu’s Arteritis

2016 ◽  
Vol 2016 ◽  
pp. 1-4
Author(s):  
Anna Maria Gruener ◽  
Pranev Sharma ◽  
Sally Ameen ◽  
Faisal Ahmed
Keyword(s):  
Side Effects ◽  
Ocular Hypertension ◽  
Inflammatory Diseases ◽  
Takayasu’S Arteritis ◽  
Takayasu's Arteritis ◽  
Ocular Side ◽  
Systemic Corticosteroids ◽  
Asymptomatic Patients ◽  
Autoimmune And Inflammatory Diseases ◽  
Systemic Side Effects

We present a rare case of severe corticosteroid-induced ocular hypertension (OHT) after prolonged systemic corticosteroid use in a young woman with Takayasu’s arteritis. As she did not sufficiently respond to ocular antihypertensive therapies, bilateral enhanced trabeculectomies were required to normalize her intraocular pressures. The systemic side effects of corticosteroids are well known, yet steroid-induced OHT and glaucoma remain silent causes of ocular morbidity. This case highlights the importance of IOP-monitoring in visually asymptomatic patients on systemic corticosteroids. It further emphasizes the need to raise awareness of the potential ocular side effects of steroids amongst physicians, in particular those looking after patients with autoimmune and inflammatory diseases.

scholarly journals From Eye Drops to ICU, a Case Report of Three Side Effects of Ophthalmic Timolol Maleate in the Same Patient

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Muhammad Asim Rana ◽  
Ahmed Fouad Mady ◽  
Basheer Abdel Rehman ◽  
Abdulrahman Alharthy ◽  
Basim Huwait ◽  
...  
Keyword(s):  
Elderly Patient ◽  
Side Effects ◽  
Beta Blockers ◽  
Systemic Absorption ◽  
Eye Drops ◽  
Timolol Maleate ◽  
Raising Awareness ◽  
Adrenergic Blocker ◽  
Life Threatening ◽  
Systemic Side Effects

Timolol Maleate (also called Timolol) is a nonselective beta-adrenergic blocker and a class II antiarrhythmic drug, which is used to treat intraocular hypertension. It has been reported to cause systemic side effects especially in elderly patients with other comorbidities. These side effects are due to systemic absorption of the drug and it is known that Timolol is measurable in the serum following ophthalmic use. Chances of life threatening side effects increase if these are coprescribed with other cardiodepressant drugs like calcium channel or systemic beta blockers. We report a case where an elderly patient was admitted with three side effects of Timolol and his condition required ICU admission with mechanical ventilation and temporary transvenous pacing. The case emphasizes the need of raising awareness among physicians of such medications about the potential side effects and drug interactions. A close liaison among patient’s physicians is suggested.

New technique to reduce systemic side effects of timolol eye drops: The tissue press method—Cross‐over clinical trial

2019 ◽  
Vol 48 (1) ◽  
pp. 24-30 ◽  
Author(s):  
Luzia Müller ◽  
Berit P. Jensen ◽  
Lucas M. Bachmann ◽  
Dickson Wong ◽  
Anthony P. Wells
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
New Technique ◽  
Eye Drops ◽  
Systemic Side Effects ◽  
Press Method

scholarly journals Safety and efficacy of reconstituted atropine 0.01% eye drops for Indian children with myopic progression

2020 ◽  
Vol 17 (2) ◽  
pp. 209-215
Author(s):  
Vidhya C. ◽  
Kaushik Murali ◽  
Sowmya R.
Keyword(s):  
Side Effects ◽  
Axial Length ◽  
Pupil Size ◽  
Eye Drops ◽  
Spherical Equivalent ◽  
Average Increase ◽  
Indian Children ◽  
Safety And Efficacy ◽  
Systemic Side Effects ◽  
Myopic Progression

Aim: To evaluate safety and efficacy of reconstituted atropine 0.01% eye drops for Indian children with myopic progression. Methods: Fifty children with progressive myopia with their spherical equivalent increasing at least 0.75 D in 6 months (0.75 to 1.50 D) were put on reconstituted atropine 0.01%. Ocular examination, including near vision, near point of accommodation (NPA), pupil size and axial length, was done. Subjective symptoms of glare and photophobia were noted. Systemic side effects were documented. Analysis was done using Microsoft Excel 2010. Results: The average age of patients was 9.5 years (range 5 to 14 years) and they were followed up for 1 year. Average mesopic and photopic pupil size was 5 and 4 mm, respectively. Average NPA was 9 cm. Mean increase in spherical equivalence was 0.18 D over 6 months. Average increase in axial length was 0.12 ± 0.11 mm over 6 months and 0.2 ± 0.29 mm over 1 year. Average increase in spherical equivalent over 6 months was 0.07 ± 0.19 D and over 1 year was 0.32 ± 0.29 D. No systemic side effects were recorded. Conclusion: Reconstituted atropine 0.01% eye drops is safe and efficacious in slowingthe progression of myopia in Indian children.

scholarly journals Systemic side effects with eye drops.

BMJ ◽  
1981 ◽  
Vol 282 (6273) ◽  
pp. 1359-1359 ◽  
Author(s):  
W D Alexander
Keyword(s):  
Side Effects ◽  
Eye Drops ◽  
Systemic Side Effects
Sign in / Sign up

Export Citation Format

Share Document